Imatinib

Kraj: Nowa Zelandia

Język: angielski

Źródło: Medsafe (Medicines Safety Authority)

Składnik aktywny:

Imatinib mesilate 478mg equivalent to Imatinib free base 400 mg

Dostępny od:

Viatris Limited

INN (International Nazwa):

Imatinib mesilate 478 mg (equivalent to Imatinib free base 400 mg)

Dawkowanie:

400 mg

Forma farmaceutyczna:

Film coated tablet

Skład:

Active: Imatinib mesilate 478mg equivalent to Imatinib free base 400 mg Excipient: Colloidal silicon dioxide Crospovidone Hypromellose Magnesium stearate Microcrystalline cellulose Opadry beige 85F97378

Typ recepty:

Prescription

Wyprodukowano przez:

Zhejiang Jiuzhou Pharmaceutical Co. Limited

Wskazania:

Imatinib Mylan is indicated for the: - treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) - treatment of adult and paediatric patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

Podsumowanie produktu:

Package - Contents - Shelf Life: Blister pack, Aclar-PVC/Aluminium - 10 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aclar - PVC/Aluminium - 30 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, HDPE with PP closure - 30 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, HDPE with PP closure - 90 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, HDPE with PP closure - 500 tablets - 24 months from date of manufacture stored at or below 25°C

Data autoryzacji:

2014-10-21